By Fineline Cube 
Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) revealed that its marketing approval filing for Quviviq (daridorexant), an anti-insomnia drug co-developed by Swiss firm Idorsia Pharmaceuticals Ltd, has been approved by the National Medical Products Administration (NMPA).
Drug Profile
Quviviq is a dual orexin receptor antagonist (DORA) that works by blocking the activation of orexin receptors, reducing arousal drive and promoting sleep without changing the sleep structure of patients. Unlike traditional insomnia drugs such as benzodiazepines, which promote sleep by calming the brain, Quviviq does not have residual effects the next day.
Global Availability
The drug is already commercially available in the US, UK, Italy, Germany, Switzerland, and Canada. Simcere Pharma acquired the exclusive development and commercialization rights for Greater China through a licensing deal with Idorsia Pharma in November 2022.-Fineline Info & Tech